Journal article
Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS)
Abstract
BACKGROUND: We undertook an angiographic, dose-finding study of staphylokinase (SAK42D variant) to evaluate its efficacy and safety in patients with acute ST-segment myocardial infarction.
METHODS AND RESULTS: Patients were studied within 6 hours of symptom onset and received SAK42D as a 30-minute infusion with 20% of the total dose given as a bolus. Eighty-two patients with a median age of 60 years (interquartile range 52 to 69 years), 84% …
Authors
Armstrong PW; Burton JR; Palisaitis D; Thompson CR; de Werf FB; Rose B; Collen D; Teo KK
Journal
American Heart Journal, Vol. 139, No. 5, pp. 820–823
Publisher
Elsevier
Publication Date
May 2000
DOI
10.1016/s0002-8703(00)90013-9
ISSN
0002-8703